On October 12, 2026, Bausch + Lomb announced that CEO Brent Saunders will depart by mutual agreement with the board, with Chairman Thomas Appio named interim chief executive effective immediately. The company did not disclose a reason for the sudden leadership change, which sent U.S.-listed shares down over 5%. Despite the leadership transition, Bausch + Lomb and majority owner Bausch Health expect to raise their 2026 adjusted EBITDA forecasts on October 28.
Story comments
Loading comments…